Marathon Petroleum (NYSE: MPC) saw its price target raised by analysts at the Royal Bank of Canada from $ 60.00 to $ 70.00 in a research note issued to investors on Wednesday, Fly reports. The brokerage currently has an “outperform” rating on the shares of the oil and gas company. The Royal Bank of Canada’s price target would indicate a potential rise of 22.16% from the company’s current price.
A number of other analysts have also weighed on MPC recently. Tudor Pickering upgraded Marathon Petroleum from a “hold” note to a “buy” note in a research note on Thursday, January 21. Raymond James upgraded Marathon Petroleum from a “market performance” rating to a “strong buy” rating and set a price target of $ 69.00 on the stock in a report on Thursday, April 22. Piper Sandler raised her price target for Marathon Petroleum shares from $ 50.00 to $ 60.00 and gave the company a rating of “overweight” in a research report on Thursday April 1. TheStreet upgraded Marathon Petroleum from a “d +” rating to a “c-” rating in a research report on Monday March 8. Finally, UBS Group assumed coverage of Marathon Petroleum in a Tuesday January 26 report. They issued a “neutral” rating and a price target of $ 47.00 for the company. Three equity research analysts rated the stock with a sustaining rating, twelve assigned a buy rating, and one issued a strong buy rating for the stock. The company currently has an average rating of “Buy” and a consensus target price of $ 53.38.
NYSE MPC opened at $ 57.30 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.84 and a debt ratio of 0.99. Marathon Petroleum has a 52 week low of $ 26.56 and a 52 week high of $ 59.93. The 50-day moving average stock price is $ 54.15, and its 200-day moving average price is $ 45.87. The company has a market cap of $ 37.32 billion, a P / E ratio of -3.79 and a beta of 2.24.
Marathon Petroleum (NYSE: MPC) last released its quarterly results on Tuesday, May 4. The oil and gas company reported earnings per share ($ 0.20) for the quarter, beating the Thomson Reuters consensus estimate of ($ 0.72) by $ 0.52. The company posted revenue of $ 22.88 billion for the quarter, compared to a consensus estimate of $ 19.80 billion. Marathon Petroleum posted a negative return on equity of 1.81% and a negative net margin of 11.11%. The company’s quarterly revenue declined 5.0% from the same quarter last year. In the same quarter of the previous year, the company achieved EPS of ($ 0.16). Research analysts predict that Marathon Petroleum will post EPS of -3.81 for the current year.
Several large investors have recently increased or reduced their holdings in MPC. TCI Wealth Advisors Inc. increased its stake in Marathon Petroleum shares by 5.3% in the first quarter. TCI Wealth Advisors Inc. now owns 4,043 shares of the oil and gas company valued at $ 216,000 after purchasing 204 additional shares in the last quarter. Parkside Financial Bank & Trust increased its stake in Marathon Petroleum by 15.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,562 shares of the oil and gas company valued at $ 65,000 after purchasing 210 additional shares in the last quarter. Stillwater Investment Management LLC increased its stake in Marathon Petroleum by 1.0% during the first quarter. Stillwater Investment Management LLC now owns 21,362 shares of the oil and gas company valued at $ 1,143,000 after acquiring 211 additional shares in the last quarter. Synovus Financial Corp increased its stake in Marathon Petroleum by 1.1% in the fourth quarter. Synovus Financial Corp now owns 19,602 shares of the oil and gas company valued at $ 810,000 after acquiring 218 additional shares in the last quarter. Finally, Center for Financial Planning Inc. strengthened its position in Marathon Petroleum shares by 11.1% in the fourth quarter. Center for Financial Planning Inc. now owns 2,608 shares of the oil and gas company valued at $ 108,000 after purchasing an additional 260 shares during the period. 73.69% of the shares are currently held by institutional investors and hedge funds.
Marathon Petroleum Company Profile
Marathon Petroleum Corp. is an independent company engaged in the refining, marketing and transportation of petroleum products in the United States. It operates through the following segments: refining and marketing; Retail; and Midstream. The Refining and Marketing segment refines crude oil and other raw materials at its refineries in the Gulf Coast and Midwestern regions of the United States; purchases ethanol and refined products for resale and distributes refined products through a variety of means, including barges, terminals and trucks that the company owns or operates.
See also: Which market index is the best?
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured article: Double list
7 health actions serving innovation in 2021
We all knew that traditional health care services were disrupted in 2020. The patient-doctor relationship has gone virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have this option available to them. And even local pharmacies have taken on a new role in e-commerce, as door-to-door pickup or door-to-door delivery of prescription drugs has become the norm.
So it’s no surprise that healthcare stocks were beaten last year. Overall, the sector was down 11%, well below the S&P 500 which climbed more than 15%.
However, the market is always looking to the future with a particular eye on innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late trials for drugs that can deliver groundbreaking results for conditions that continue to plague our world.
This is the object of this presentation. We have identified 7 healthcare actions that offer innovative ideas that will help improve patient outcomes. And in some cases, it will completely revolutionize medicine. These are also the stocks that analysts are looking for.
See the “7 healthcare stocks for innovation in 2021”.